跳至主要内容
临床试验/NCT00469131
NCT00469131已完成3 期

Randomized Comparative Study on Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparison Between Tacrolimus + MMF and Tacrolimus + Steroid

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan1 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2003年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
79
试验地点
1
主要终点
Event-free survival time at the end of first year after living liver transplantation.

研究概览

简要总结

The aim of this study is to compare immunosuppression protocol of tacrolimus + MMF with that of tacrolimus + steroid for preventing recurrence of hepatitis C after living donor liver transplantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 69 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recipient of living donor liver transplantation for HCV-related cirrhosis

排除标准

  • ABO blood type incompatible transplant case
  • Renal dysfunction (serum creatinine >2.0 mg/dL)
  • WBC < 1,000/mm3
  • Hemoglobin < 8 g/dL
  • Platelet <30,000 /mm3

研究组 & 干预措施

1 Drug:

Active Comparator

tacrolimus + steroid

干预措施: tacrolimus + steroid (Drug)

2 Drug:

Active Comparator

tacrolimus + mycophenolate mofetil

干预措施: tacrolimus + mycophenolate mofetil (Drug)

结局指标

主要结局

Event-free survival time at the end of first year after living liver transplantation.

时间窗: 1 year

次要结局

  • HCV-RNA value, patient survival, recurrence-free survival, rate of interferon therapy induction, rate of steroid pulse for rejection, chronic rejection(1 year)

研究者

发起方
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
申办方类型
Other

研究点 (1)

Loading locations...

相似试验